Capecitabine Tolerance of EU vs US Patients
Why are European patients better able to tolerate high doses of capecitabine than US patients?
Diagnosis & Disease Information
Sarcopenia Affects Dose in Reinduction Therapy for Metastatic Colorectal Cancer
Sarcopenia is significantly associated with dose reductions but not with dose-limiting toxicities at initiation of CAPOX-B reinduction therapy in patients with mCRC, researchers reported at ESMO 2017 Congress.
Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.
Drug-Drug Interaction Between Capecitabine and PPIs Reduces Survival in GI Cancers
Drug-drug interaction between capecitabine and common heartburn medications has a negative effect on progression-free survival and overall survival in patients with GI cancer.
Adjuvant Gemcitabine/Capecitabine: New Standard of Care for Resected Pancreatic Cancer
Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.
A roundup of FDA oncology news from September 2013
The FDA approved Perjeta (pertuzumab) for the neoadjuvant treatment of breast cancer, first generic version of Xeloda (capecitabine) has gained FDA approval, and other FDA actions.
First generic version of Xeloda FDA approved
A generic version of the oral chemotherapy drug Xeloda (capecitabine) has been approved by the U.S. Food and Drug Administration to treat cancers of the colon/rectum or breast.
Eribulin has greater overall survival benefit than capecitabine for metastatic breast cancer
In women with previously treated metastatic breast cancer who shared certain traits, treatment with the newer chemotherapy agent eribulin mesylate had increased benefit over capecitabine.
Eribulin may be useful earlier in breast cancer
A drug used for metastatic breast cancer after several previous treatments may improve survival when administered earlier in the disease course.
Combination therapy in metastatic CRC
Adding cetuximab to the treatment regimen of patients with metastatic colorectal cancer (CRC) results in worse outcomes, a controlled trial has shown.
- Loading...
Loading...
Loading... 
Loading...